Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
targeted therapies
Biotech
Tyra banks $173M to bring cancer resistance programs into clinic
Tyra is the latest biotech to rake in an upsized IPO. Its $172.8 million deal will advance three programs targeting drug-resistant cancers.
Amirah Al Idrus
Sep 15, 2021 10:20am
AstraZeneca, Thermo Fisher launch multiyear diagnostic project
Sep 1, 2021 10:45am
Nuvalent banks $166M IPO to push resistance-beating cancer drugs
Jul 29, 2021 11:20am
Erasca nabs $300M IPO to attack cancer's favorite pathway
Jul 16, 2021 10:10am
Ionis pays $45M to expand oligonucleotide delivery toolkit
Jul 13, 2021 8:20am
Blueprint adds another BMS vet to its roster with new CSO
May 17, 2021 10:25am
